Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go?
Childhood obesity and its sequelae, including metabolic syndrome, are reaching epidemic proportions worldwide. Young people treated with antipsychotic medication are particularly at risk as they experience significant weight gain as a side effect of second generation antipsychotics (SGAs) with consequent increased risk of type 2 diabetes, cardiovascular morbidity and metabolic syndrome. However, surveillance for these side effects is not carried out nor intervention offered in routine clinical prctice. This paper examines the current state of evidence on this topic and suggests directions for future research and clinical practice. Systematic monitoring and preventative programs aimed at weight gain and metabolic side effects should form an integral part of the comprehensive management of adolescents on SGAs.